- Home
- SBFM vs INDP Comparison
SBFM vs INDP Comparison
Compare SBFM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBFM | INDP |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SBFM | INDP |
|---|---|---|
| Price | $1.23 | $2.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 48.9K | ★ 1.8M |
| Earning Date | 11-13-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,323,742.00 | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $32.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.24 | N/A |
| 52 Week Low | $1.16 | $1.65 |
| 52 Week High | $3.90 | $47.60 |
Technical Indicators
Market Signals| Indicator | SBFM | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 48.69 |
| Support Level | $1.20 | $2.60 |
| Resistance Level | $1.29 | $3.66 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 8.70 | 23.20 |
Price Performance
Historical ComparisonAbout SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.